Venture Visionary Partners LLC Decreases Stake in Zoetis Inc. $ZTS

Venture Visionary Partners LLC reduced its position in Zoetis Inc. (NYSE:ZTSFree Report) by 59.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,679 shares of the company’s stock after selling 5,441 shares during the period. Venture Visionary Partners LLC’s holdings in Zoetis were worth $606,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Zoetis in the 4th quarter valued at about $216,000. First Trust Advisors LP raised its stake in shares of Zoetis by 134.8% in the 4th quarter. First Trust Advisors LP now owns 104,496 shares of the company’s stock valued at $17,026,000 after purchasing an additional 59,990 shares in the last quarter. Alta Advisers Ltd raised its stake in shares of Zoetis by 26.9% in the 4th quarter. Alta Advisers Ltd now owns 1,523 shares of the company’s stock valued at $248,000 after purchasing an additional 323 shares in the last quarter. Finally, Pinebridge Investments L.P. raised its stake in shares of Zoetis by 64.1% in the 4th quarter. Pinebridge Investments L.P. now owns 167,301 shares of the company’s stock valued at $27,258,000 after purchasing an additional 65,342 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $156.6940 on Thursday. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $69.44 billion, a price-to-earnings ratio of 26.97, a price-to-earnings-growth ratio of 2.50 and a beta of 0.88. The company has a 50-day moving average price of $154.27 and a two-hundred day moving average price of $158.86.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZTS shares. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $202.43.

Get Our Latest Report on Zoetis

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.18% of the stock is owned by company insiders.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.